Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| U S PHYSICAL THERAPY INC /NVUSPH · Entity 379 | Former Director, Exec VP, CFO | March 05, 2021 | March 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
U S PHYSICAL THERAPY INC /NV
Report date March 05, 2021 · Filed March 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,582 |
Ending reported balance
After 2021-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-03-05 · Sale · Disposed 2,500 · Balance 9,082 F1: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.21 to $111.51 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Row 2 · 2021-03-05 · Sale · Disposed 2,500 · Balance 6,582 F2: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.00 to $111.19 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.21 to $111.51 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.00 to $111.19 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2021 Filed Mar 8, 2021 19:43 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 2,500 | $110.54 | $276,350.00 |
DisclosureSEC source: 0001209191-21-018483 · doc4.xml · nonDerivative · entry 2 MCAFEE LAWRANCE W · CIK 0001263096 · Former Director, Exec VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,582 F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.00 to $111.19 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 19:43 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 2,500 | $110.97 | $277,425.00 |
DisclosureSEC source: 0001209191-21-018483 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Former Director, Exec VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,082 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.21 to $111.51 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 21:45 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 5,000 | $119.14 | $595,700.00 |
DisclosureSEC source: 0001209191-21-015262 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Former Director, Exec VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,582 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.00 to $120.00 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 20:12 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 2,222 | $112.22 | $249,352.84 |
DisclosureSEC source: 0001209191-20-057587 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Former Exec VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,852 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.76 to $112.56, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 15,052 shares which restrictions lapse as to 2,229 shares on January 1, 2021; 1704 shares on each of April 1, July 1 and October 1, 2021; 1,712 shares on January 1, 2022; 1,072 shares on each of April 1, July 1 and October 1, 2022; 1,075 shares on January 1, 2023; 424 shares on each of April 1, July 1 and October 1 2023 and 436 shares on January 1, 2024, if he is employed by the Company on those dates. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 23:51 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 4,450 | $91.41 | $406,774.50 |
DisclosureSEC source: 0001209191-20-046245 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,074 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.84 to $92.83 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 17,266 shares which restrictions lapse as to 2,214 shares on October 1, 2020; 2,229 shares on January 1, 2021; 1704 shares on each of April 1, July 1 and October 1, 2021; 1,712 shares on January 1, 2022; 1,072 shares on each of April 1, July 1 and October 1, 2022; 1,075 shares on January 1, 2023; 424 shares on each of April 1, July 1 and October 1 2023 and 436 shares on January 1, 2024, if he is employed by the Company on those dates. Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:50 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 3,000 | $107.58 | $322,740.00 |
DisclosureSEC source: 0001209191-20-016645 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,524 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.00 to $108.55 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 21,694 shares which restrictions lapse as to 2,214 shares on each of April 1, July 1 and October 1, 2020; 2,229 shares on January 1, 2021; 1704 shares on each of April 1, July 1 and October 1, 2021; 1,712 shares on January 1, 2022; 1,072 shares on each of April 1, July 1 and October 1, 2022; 1,075 shares on January 1, 2023; 424 shares on each of April 1, July 1 and October 1 2023 and 436 shares on January 1, 2024, if he is employed by the Company on those dates. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:19 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | GrantCommon Stock | 6,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016490 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,524 F1 · shares: The 6,796 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installment with the 424 shares on April 1, 2020 and thereafter with 424 shares on April 1, July 1, October 1 and January 1 of each year with the final 436 shares lapsing on January 1, 2024, if he is employed by the Company on those dates. F2 · balance_after: Includes 21,694 shares which restrictions lapse as to 2,214 shares on each of April 1, July 1 and October 1, 2020; 2,229 shares on January 1, 2021; 1704 shares on each of April 1, July 1 and October 1, 2021; 1,712 shares on January 1, 2022; 1,072 shares on each of April 1, July 1 and October 1, 2022; 1,075 shares on January 1, 2023; 424 shares on each of April 1, July 1 and October 1 2023 and 436 shares on January 1, 2024, if he is employed by the Company on those dates. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 17:05 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 1,598 | $113.52 | $181,404.96 |
DisclosureSEC source: 0001209191-19-058051 · doc4.xml · nonDerivative · entry 2 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,728 F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $113.00 to $114.11 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 17,398 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 17:05 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 402 | $116.42 | $46,800.84 |
DisclosureSEC source: 0001209191-19-058051 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,326 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $116.00 to $116.54 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 17,398 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 18:25 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 1,300 | $130.55 | $169,715.00 |
DisclosureSEC source: 0001209191-19-045468 · doc4.xml · nonDerivative · entry 2 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,728 F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.07 to $131.01 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 19,898 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 18:25 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 1,200 | $132.53 | $159,036.00 |
DisclosureSEC source: 0001209191-19-045468 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,028 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.02 to $133.45 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 19,898 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023. Read SEC document |
| May 03, 2019 Filed May 6, 2019 16:42 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 2,500 | $116.86 | $292,150.00 |
DisclosureSEC source: 0001209191-19-027652 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,228 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $115.70 to $117.30 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 22,398 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of July 1, 2019, October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 20:07 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 3,150 | $106.43 | $335,254.50 |
DisclosureSEC source: 0001209191-19-018398 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,728 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.00 to $107.04 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 24,898 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021 and 1,288 shares on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 22:11 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | GrantCommon Stock | 10,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016715 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,878 F1 · shares: The 10,371 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installment with the 648 shares on April 1, 2019 and thereafter with 648 shares on April 1, July 1, October 1 and January 1 of each year with the final 651 shares lapsing on January 1, 2023. F2 · balance_after: Includes 24,898 shares, inclusive of the 10,371 shares in footnote 1, of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1288 shares on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 20:20 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 3,100 | $113.29 | $351,199.00 |
DisclosureSEC source: 0001209191-18-057342 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,507 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $112.00 - $115.49, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 17,629 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:24 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 3,100 | $115.59 | $358,329.00 |
DisclosureSEC source: 0001209191-18-045526 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,607 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $114.00 - $116.80, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 20,731 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| May 04, 2018 Filed May 7, 2018 18:36 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | Disposition to issuerCommon Stock | 2,900 | $87.42 | $253,518.00 |
DisclosureSEC source: 0001209191-18-028269 · doc4.xml · nonDerivative · entry 2 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,707 F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.20 to $87.90, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F1 · balance_after: Includes 23,833 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| May 04, 2018 Filed May 7, 2018 18:36 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | Disposition to issuerCommon Stock | 700 | $87.00 | $60,900.00 |
DisclosureSEC source: 0001209191-18-028269 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,607 F1 · balance_after: Includes 23,833 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 19:02 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 2,000 | $86.06 | $172,120.00 |
DisclosureSEC source: 0001209191-18-019095 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,307 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.60 - $86.60, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 26,935 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 16:04 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 5,000 | $83.35 | $416,750.00 |
DisclosureSEC source: 0001209191-18-018734 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,307 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.05 - $83.55, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 26,935 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 19:43 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | GrantCommon Stock | 10,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017651 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,307 F1 · shares: The 10,120 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installment with the first 15 installments of 632 shares each beginning on April 1, 2018 and thereafter with 632 shares on April 1, July 1, October 1 and January 1 of each year with the final 640 shares lapsing on January 1, 2022. F2 · balance_after: Includes the above mentioned shares and 16,185 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 16:56 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 2,000 | $72.56 | $145,120.00 |
DisclosureSEC source: 0001209191-17-065362 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,187 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.25 - $72.75, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes the 20,230 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,415 shares on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 15:56 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 2,000 | $68.68 | $137,360.00 |
DisclosureSEC source: 0001209191-17-061368 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,187 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.38- $69.15, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes the 20,230 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,415 shares on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021. Read SEC document |
| November 08, 2017 Filed Nov 9, 2017 17:37 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 5,200 | $66.37 | $345,124.00 |
DisclosureSEC source: 0001209191-17-059923 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,387 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.00- $66.58, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes the 20,230 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,415 shares on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 20:16 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 400 | $68.18 | $27,272.00 |
DisclosureSEC source: 0001209191-17-059575 · doc4.xml · nonDerivative · entry 2 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,587 F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.05 - $68.33, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes the 20,230 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,415 shares on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 20:16 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 400 | $70.23 | $28,092.00 |
DisclosureSEC source: 0001209191-17-059575 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,987 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.15 - $70.35, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes the 20,230 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,415 shares on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 14:28 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 3,000 | $62.04 | $186,120.00 |
DisclosureSEC source: 0001209191-17-048682 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,387 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.00- $62.20, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes the 23,637 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,407 on October 1, 2017; 3,415 on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021. Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 15:04 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | GrantCommon Stock | 8,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-023049 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,387 F1 · shares: The 8,175 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installment with the first 15 installments of 510 shares each beginning on April 1, 2017 and thereafter with 510 on April 1, July 1, October 1 and January 1 of each year with the final 525 shares lapsing on January 1, 2021. F2 · balance_after: Includes the 8,175 shares recently granted and 22,276 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,407 on each of April 1, 2017, July 1, 2017, and October 1, 2017; 3,415 on January 1, 2018; 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021. Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 22:24 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 2,000 | $62.55 | $125,100.00 |
DisclosureSEC source: 0001209191-16-151757 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,212 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.25 - $62.60, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 26,323 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 4,047 shares on January 1, 2017; 2,897 on each of April 1, 2017, July 1, 2017, and October 1, 2017; 2,905 on January 1, 2018; 1,960 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; and 710 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 15:19 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | SaleCommon Stock | 2,000 | $58.04 | $116,080.00 |
DisclosureSEC source: 0001209191-16-149560 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,212 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.00-$58.08, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 26,323 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 4,047 shares on January 1, 2017; 2,897 on each of April 1, 2017, July 1, 2017, and October 1, 2017; 2,905 on January 1, 2018; 1,960 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; and 710 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020. Read SEC document |
| September 19, 2016 Filed Sep 19, 2016 19:29 UTC | U S PHYSICAL THERAPY INC /NV USPH · Entity 379 | Salecommon stock | 2,000 | $64.00 | $128,000.00 |
DisclosureSEC source: 0001209191-16-141956 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,212 F1 · balance_after: Includes 30,370 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 4,047 shares on each of October 1, 2016, January 1, 2017; 2,897 on each of April 1, 2017, July 1, 2017, and October 1, 2017; 2,905 on January 1, 2018; 1,960 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; and 710 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.